[go: up one dir, main page]

CA3272746A1 - Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis - Google Patents

Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis

Info

Publication number
CA3272746A1
CA3272746A1 CA3272746A CA3272746A CA3272746A1 CA 3272746 A1 CA3272746 A1 CA 3272746A1 CA 3272746 A CA3272746 A CA 3272746A CA 3272746 A CA3272746 A CA 3272746A CA 3272746 A1 CA3272746 A1 CA 3272746A1
Authority
CA
Canada
Prior art keywords
hemochromatosis
hfe
hereditary
treatment
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3272746A
Other languages
French (fr)
Inventor
Marko Potman
Aliye Seda Yilmaz-Elis
Aron KOS
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Publication of CA3272746A1 publication Critical patent/CA3272746A1/en
Pending legal-status Critical Current

Links

CA3272746A 2022-11-24 2023-11-23 Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis Pending CA3272746A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2217580.6 2022-11-24
GB2306060.1 2023-04-25

Publications (1)

Publication Number Publication Date
CA3272746A1 true CA3272746A1 (en) 2024-05-30

Family

ID=

Similar Documents

Publication Publication Date Title
AU2024246572A1 (en) Antisense oligonucleotides for the treatment of liver disease
IL284417A (en) Antisense oligonucleotides for the treatment of leber's congenital amaurosis
CA3272746A1 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
AU2023390632A1 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
CA3256609A1 (en) Syf2 antisense oligonucleotides
GB202306060D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202217580D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
CA3294368A1 (en) Antisense oligonucleotides for the treatment of neurodegenerative disease
CA3286425A1 (en) Antisense oligonucleotides for the treatment of liver disease
CA3294622A1 (en) Antisense treatment
CA3267171A1 (en) Antisense oligonucleotides for the treatment of canavan disease
CA3286002A1 (en) Antisense oligonucleotides for the treatment of neurological disorders
CA3280043A1 (en) Syf2 antisense oligonucleotides
CA3269690A1 (en) Antisense oligonucleotides for treatment of usher 2a. exons 30-31
CA3300599A1 (en) Antisense oligonucleotides for treatment of usher 2a. exon 53
CA3271562A1 (en) Antisense oligonucleotides for treatment of usher 2a. exons 39-40
GB202502460D0 (en) Antisense oligonucleotides for the treatment of cancer
GB202400404D0 (en) Antisense oligonucleotides for the treatment of polg-related disorders
GB202418430D0 (en) Antisense oligonucleotides for the treatment of migrane
GB202318087D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202304438D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202112319D0 (en) Antisense oligonucleotides for the treatment of cadasil
GB202417404D0 (en) Antisense oligonucleotides for the treatment of kidney disorders
HK40085033A (en) Tafoxiparin for the treatment of preeclampsia
GB202502332D0 (en) Antisense oligonucleotides for the treatment of liver cancer